Introduction {#section1-1533033818808507}
============

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4 million cases and 693 900 deaths occurring in 2012.^[@bibr1-1533033818808507]^ Molecular markers for the biological behavior and prognosis of CRC were extensively studied; among these markers, DNA mismatch repair (MMR) was proposed to play a pivotal role in the development and prognosis of CRC.^[@bibr2-1533033818808507]^

Approximately 10% to 20% of sporadic CRC is associated with impaired function of DNA MMR genes.^[@bibr3-1533033818808507]^ Mismatch repair genes encode corresponding enzymes that can recognize and repair mismatched base pairs during DNA replication. Deficient MMR leads to genetic instability and accounts for the accumulation of widespread alterations in the length of short repeated DNA sequences, known as microsatellite instability (MSI). The accelerating accumulation of gene mutations in proto-oncogenes and cancer suppressor genes because of aberrant MMR can affect the proliferation of normal cells and promote the development of carcinoma.^[@bibr4-1533033818808507][@bibr5-1533033818808507]-[@bibr6-1533033818808507]^ A meta-analysis by Guastadisegni, including 31 eligible studies reporting survival in 12 782 patients with CRC, showed that MSI predicted favorable prognosis, with both longer overall survival (OS) and disease-free survival (DFS).^[@bibr7-1533033818808507]^ However, the detection of MSI by polymerase chain reaction (PCR) in 5 highly monomorphic mononucleotidic microsatellite markers (BAT26, BAT25, NR21, NR24, NR27) is complex and costly, limiting its application in the clinic. Currently, different MMR genes (hMLH1, hMSH2, hMSH3, hMSH6, hPMSH1, and hPMSH2) have been identified to cause the development of MSI.^[@bibr8-1533033818808507]^ The hMLH1 and hMSH2 account for more than 90% of MSI development. Thus, their relationship with the development and prognosis of CRC has been extensively studied.^[@bibr9-1533033818808507][@bibr10-1533033818808507][@bibr11-1533033818808507][@bibr12-1533033818808507][@bibr13-1533033818808507][@bibr14-1533033818808507][@bibr15-1533033818808507][@bibr16-1533033818808507][@bibr17-1533033818808507]-[@bibr18-1533033818808507]^ However, the results were controversial. Thus, the aim of this meta-analysis is to identify the association between deficient MMR and the prognosis of CRC.

Materials and Methods {#section2-1533033818808507}
=====================

Search Strategy {#section3-1533033818808507}
---------------

A meta-analysis was conducted according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.^[@bibr19-1533033818808507]^ Two reviewers (JTH and XLC) independently searched the following databases from their inceptions to June 1st, 2017: PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. The search terms included the following:"colorectal cancer" OR "colon cancer" OR "rectal cancer""mismatch repair gene" OR "hMLH1" OR "hMSH2" OR "hMSH3" OR "hMSH6" OR "hPMSH1" OR "hPMSH2" OR MMR"prognosis" OR "prognoses" OR "prognostic" OR "predictive" OR "biomarker" OR "marker" OR "survival" OR "survive" OR "Cox" OR "Logrank" OR "Kaplan-Meier"

The search was not limited by language. The potentially relevant studies were manually reviewed in the relevant systematic reviews and meta-analysis. The relevant studies were also obtained by searching Google scholar with the search terms "colorectal cancer, colon cancer, or rectal cancer," "mismatch repair gene," and "prognosis, predictive, or survive."

Inclusion Criteria {#section4-1533033818808507}
------------------

The inclusion criteria included the following: (1) patients who were diagnosed with primary CRC (including colon cancer, or rectal cancer) were included. Patients exhibiting different clinical stages, histological types, or treatment methods were all included; (2) the expression of MMR genes was measured using PCR, immunohistochemistry (IHC), or enzyme-linked immunosorbent assay in the CRC tissue; (3) the association between MMR with patient prognosis was investigated, and the hazard ratio (HR), its 95% confidence interval (CI), or the relevant information were provided; and (4) a full paper was published. When the same team reported several studies from the same patients, the most recent study was included. Studies published in the abstract were excluded.

Study Selection {#section5-1533033818808507}
---------------

The same studies from the different databases were identified. The titles and abstracts were read for eligibility by 2 of the 3 authors (DJZ, PRL, or LZC). The full texts of potentially eligible studies were retrieved and reviewed independently by 2 authors (HBL and DJZ). Any disagreements were recorded and resolved by consensus under the guidance of another author (XLC).

Data Collection {#section6-1533033818808507}
---------------

The data in the eligible studies were extracted by 2 authors (JTH and DJZ). The study information (the first author, the year of publication), study participants (the type of patients, gender, mean age, and sample size), the characteristics of treatment (surgery, chemotherapy, radiotherapy), the characteristics of MMR (gene subtype, test sample, test content, test method), and the prognostic outcomes of interest (OS, DFS, and/or relapse-free survival) were extracted. If the relevant data were not reported in the study, the item was recorded as "NR (not reported)."

Data Analysis {#section7-1533033818808507}
-------------

The MMR genes were classified as either "deficiency" (weak or negative) or "proficiency" (strong or positive). If the HRs and their 95% CI were reported explicitly in the study, the data were collected. If these data were not reported explicitly, they were calculated from the available numerical data or survival curves using the methods reported by Tierney *et al*.^[@bibr20-1533033818808507]^ The meta-analysis was conducted according to 2 types of indexes, OS, and DFS.

To measure the impact of deficient MMR on survival time, the combined HR and its 95% CI were calculated. The heterogeneity of the individual HR was calculated with a χ^2^ test. The heterogeneity test with the inconsistency index (*I* ^2^) statistic and *Q* statistic was performed. For the *Q* statistic, a *P* value of less than 0.1 was considered representative of statistically significant heterogeneity. The *I* ^2^ is the proportion of total variation contributed by between-study variation. An *I* ^2^ index of approximately 25% was considered to demonstrate low levels of heterogeneity, 50% was considered medium, and 75% was considered high. The sensitivity analysis were conducted by reestimating the pooled HR and omitting each study in turn to investigate the influence of each individual study on the overall meta-analysis summary estimate. Furthermore, subgroup analysis based on geographical regions (Asia, West \[Europe and America\]), different subtypes of gene (MMR, hMSH2, hMLH1), and different methods for detection of MMR (IHC, PCR) were performed to clarify the source of heterogeneity. In addition, the heterogeneity of the effect was discovered using meta-regression, including country, type of patient, sample size (≤200, and \>200), test content, analysis method, subtype of gene, and therapy methods as covariates. Heterogeneity was defined as a *P* ≤ .05. An observed HR \>1 implied a worse prognosis in the high expression of MMR compared to the low expression of MMR. Publication bias and small study effects were assessed by Begg test and Egger test, with *P* \< .05 considered to show significant publication bias. All of the calculations were performed by STATA version 12.0.

Results {#section8-1533033818808507}
=======

The Characteristics of the Studies {#section9-1533033818808507}
----------------------------------

A total of 849 studies met the inclusion criteria ([Figure 1](#fig1-1533033818808507){ref-type="fig"}), of which 232 studies were excluded for duplicates, and 553 studies were excluded by reviewing the titles and abstracts. The full texts of the remaining 64 studies were obtained for review. Eventually, 21 studies were included in the meta-analysis.^[@bibr9-1533033818808507][@bibr10-1533033818808507][@bibr11-1533033818808507][@bibr12-1533033818808507][@bibr13-1533033818808507][@bibr14-1533033818808507][@bibr15-1533033818808507][@bibr16-1533033818808507][@bibr17-1533033818808507]-[@bibr18-1533033818808507],[@bibr21-1533033818808507][@bibr22-1533033818808507][@bibr23-1533033818808507][@bibr24-1533033818808507][@bibr25-1533033818808507][@bibr26-1533033818808507][@bibr27-1533033818808507][@bibr28-1533033818808507][@bibr29-1533033818808507][@bibr30-1533033818808507]-[@bibr31-1533033818808507]^

![Flow chart of the search strategy.](10.1177_1533033818808507-fig1){#fig1-1533033818808507}

The characteristics of the included studies are shown in [Table 1](#table1-1533033818808507){ref-type="table"}. Twenty-one studies contained a total of 5340 patients with CRC. All the studies were published from 1999 to 2016. Of the 21 studies, 15 studies reported OS and 10 reported DFS ([Table 2](#table2-1533033818808507){ref-type="table"}).

###### 

The Main Characteristics of the Included Studies.

![](10.1177_1533033818808507-table1)

  Author         Year of Publication   Country   Time        Patients        Sample Size   Male   Mean of Age (range)   Stage     Surgery Treatment   Chemotherapy   Radiotherapy   Median Follow-Up Month (Range)
  -------------- --------------------- --------- ----------- --------------- ------------- ------ --------------------- --------- ------------------- -------------- -------------- --------------------------------
  Bendardaf R    2008                  Finland   1996-2003   CRC             73            46     57.9 (NR)             II-IV     Partial             All            No patient     32.6 (NR)
  Cawkwell L     1999                  UK        NR          CRC             101           NR     \>50 (NR)             NR        NR                  NR             NR             60.0 (NR)
  Huh JW         2016                  Korea     NR          Rectal cancer   209           136    56 (27-81)            II, III   All                 All            All            44 (2-87)
  Ide T          2008                  Japan     1999-2005   CRC             94            60     68.2 (40-87)          I-IV      All                 All            NR             26.1 (NR)
  Jansson A      2003                  Sweden    1972-1996   CRC             301           NR     70 (34-94)            I-IV      All                 NR             NR             NR (NR)
  Jensen LH      2007                  Denmark   NR          CRC             28            13     61 (49-74)            III-IV    NR                  All            NR             12.2 (6.7-20.2)
  Jensen SA      2009                  Denmark   1996-2003   CRC             340           159    NR (NR)               II-IV     NR                  All            NR             6.1 (4.1-11.3)
  Langner E      2010                  Poland    NR          CRC             75            45     NR (NR)               I-IV      All                 NR             NR             NR (NR)
  Lanza G        2006                  Italy     1986-1995   CRC             718           359    65 (27-85)            II, III   Partial             Most           Partial        90.5 (63-144)
  Ma J           2015                  China     2008-2011   Colon cancer    184           111    NR (NR)               NR        NR                  All            NR             17.6 (7-36)
  Park JW        2010                  Korea     2001-2003   CRC             318           191    60.5 (27-87)          I-IV      All                 Partial        NR             24.0 (NR)
  Pu C           2015                  China     2005-2008   CRC             327           201    NR (NR)               I-IV      NR                  Partial        NR             24.0 (NR)
  Rau B          2003                  Germany   1993-1999   CRC             66            41     59 (39-74)            NR        NR                  All            All            39.3 (11.3-83.4)
  Russo A        2009                  Italy     NR          CRC             526           288    48 (20-88)            I-IV      NR                  NR             NR             64 (6-383)
  Sinicrope FA   2006                  USA       NR          Colon cancer    528           274    NR (NR)               II, III   NR                  All            NR             NR (NR)
  Smyth EF       2004                  UK        1995-1998   Colon cancer    111           NR     72 (3990)             I-IV      All                 NR             NR             NR (NR)
  Sun Z          2014                  China     2009-2012   CRC             404           233    NR (NR)               I-IV      NR                  NR             NR             \>36 (NR)
  Wang H         2014                  China     2005-2008   CRC             327           201    58.7 (2581)           I-IV      NR                  NR             NR             60.0 (NR)
  Wang JB        2016                  China     2011-2012   Colon cancer    90            58     NR (NR)               II, III   All                 Partial        NR             27 (5-35)
  Wang Y         2014                  China     NR          CRC             433           254    58.6 (2482)           I-IV      All                 Partial        Partial        52 (1-87)
  Wu HW          2013                  China     2004-2006   CRC             87            56     59 (35-82)            I-III     All                 NR             NR             60.0 (NR)

Abbreviations: CRC, colorectal cancer; NR, not report.

###### 

The Gene and Results of the Included Studies.

![](10.1177_1533033818808507-table2)

  Author         Subtypes of Gene   Test Sample   Test Content   Test Method   Analysis Method   Survival Type
  -------------- ------------------ ------------- -------------- ------------- ----------------- ---------------
  Bendardaf R    MMR                Tissue        Protein        IHC           Univariate        DFS
  Cawkwell L     MMR                Tissue        Protein        IHC           Univariate        OS
  Huh JW         hMSH2              Tissue        Protein        IHC           Multivariate      DFS
  Ide T          hMLH1              Tissue        mRNA           PCR           Univariate        DFS
  Jansson A      hMSH2              Tissue        Protein        IHC           Univariate        OS
  Jensen LH      hMSH2              Tissue        RNA            PCR           Univariate        OS
  Jensen SA      MMR                Tissue        Protein        IHC           Multivariate      OS, RFS
  Langner E      hMSH2              Tissue        RNA            PCR           Univariate        OS
  Lanza G        MMR                Tissue        Protein        IHC           Multivariate      OS
  Ma J           MMR                Tissue        Protein        IHC           Multivariate      OS, DFS
  Park JW        MMR                Tissue        Protein        IHC           Multivariate      OS
  Pu C           hMLH1              Tissue        Protein        IHC           Multivariate      DFS
  Rau B          hMSH2              Tissue        Protein        IHC           Univariate        OS, DFS
  Russo A        MMR                Blood         mRNA           PCR           Multivariate      OS
  Sinicrope FA   MMR                Tissue        Protein        IHC           Univariate        OS, DFS
  Smyth EF       hMLH1              Tissue        Protein        IHC           Multivariate      OS
  Sun Z          MMR                Tissue        Protein        IHC           Univariate        DFS
  Wang H         hMSH2              Tissue        Protein        IHC           Multivariate      OS
  Wang JB        MMR\*              Tissue        Protein        IHC           Univariate        OS
  Wang Y         MMR                Blood         DNA            PCR           Multivariate      OS
  Wu HW          hMSH2              Tissue        Protein        IHC           Multivariate      DFS

Abbreviations: DFS, disease-free survival; DNA, deoxyribonucleic acid; IHC, immunohistochemistry; MMR, contain hMLH1, hMSH2; MMR\*, contain hMLH1, hMSH2, hMSH6, and hPMS2; mRNA, messenger RNA; Multivariate, multivariate survival analysis; OS, overall survival; PCR, polymerase chain reaction; RFS, recurrence-free survival (which was used as DFS); RNA, ribonucleic acid; Univariate, univariate survival analysis.

Meta-Analysis for OS {#section10-1533033818808507}
--------------------

Fifteen studies of MMR for OS in patients with CRC were included in the meta-analysis. There was no significant heterogeneity across 15 studies with OS (*I* ^2^ = 32.0%, *P* = 0.113; [Figure 2](#fig2-1533033818808507){ref-type="fig"}). The combined HR of the 15 studies was 0.59 (95% CI: 0.50-0.69; [Figure 2](#fig2-1533033818808507){ref-type="fig"}). Mismatch ratio was significantly associated with improved prognosis in Asian studies (HR: 0.67; 95% CI: 0.50-0.91; [Figure 3](#fig3-1533033818808507){ref-type="fig"}) and western studies (HR: 0.56; 95% CI: 0.46-0.67; [Figure 3](#fig3-1533033818808507){ref-type="fig"}). The HR was 0.58 (95% CI: 0.45-0.75) for MMR as a marker in 10 studies, 0.29 (95% CI: 0.10-0.87) for hMLH1 as a marker in one study, and 0.48 (95% CI: 0.30-0.77) for hMSH2 as a marker in 4 studies ([Table 3](#table3-1533033818808507){ref-type="table"}; [Figure 3](#fig3-1533033818808507){ref-type="fig"}). When the subgroups were analyzed based on the test method, the combined HRs for IHC and PCR were 0.51 (95% CI: 0.42-0.62) and 0.74 (95% CI: 0.57-0.96), respectively ([Figure 3](#fig3-1533033818808507){ref-type="fig"}).

![Forest plot for the association between MMR expression and OS in CRC.\
CRC indicates colorectal cancer; MMR, mismatch repair; OS, overall survival.](10.1177_1533033818808507-fig2){#fig2-1533033818808507}

![Subgroup analysis for the association between MMR expression and OS in CRC. A, different geographical regions (Asia, west); (B) different subtypes of gene (MMR, hMSH2, hMLH1); (C) different methods for detection of MMR (immunohistochemistry \[IHC\], polymerase chain reaction \[PCR\]). CRC indicates colorectal cancer; MMR, mismatch repair; OS, overall survival.](10.1177_1533033818808507-fig3){#fig3-1533033818808507}

###### 

The Results of the Meta-Analysis.

![](10.1177_1533033818808507-table3)

                          Number of Studies   Patients   HR (95% CI)           Heterogeneity (*I* ^2^, *P*)
  ----------------------- ------------------- ---------- --------------------- ------------------------------
  Overall survival                                                             
   All                    15                  4146       0.59 (0.50-0.69)      32.0%, 0.113
    Asian                 5                   1352       0.67 (0.50-0.91)      50.4%, 0.089
    Western               10                  2794       0.56 (0.46-0.67)      20.9%, 0.251
   Gene                                                                        
    MMR                   10                  3539       0.58 (0.45-0.75)^a^   47.3%, 0.047
    hMSH2                 4                   496        0.48 (0.30-0.77)      0.0%, 0.805
    hMLH1                 1                   111        0.29 (0.10-0.87)      NR
   Test method                                                                 
    IHC                   11                  3084       0.51 (0.42-0.62)      9.7%, 0.351
    PCR                   4                   1062       0.74 (0.57-0.96)      33.4%, 0.212
  Disease-free survival                                                        
   All                    10                  2312       0.62 (0.44-0.88)      66.5%, 0.001
   All^b^                 9                   2239       0.57 (0.43-0.75)      48.0%, 0.052
    Asian                 6                   1305       0.62 (0.50-0.78)^a^   61.9%, 0.022
    Western               3                   934        0.55 (0.38-0.81)      0.0%, 0.373
   Gene                                                                        
    MMR                   4                   1456       0.61 (0.47-0.79)      0.0%, 0.493
    hMLH1                 2                   421        0.32 (0.17-0.58)^a^   79.2%, 0.028
    hMSH2                 3                   362        0.72 (0.52-1.00)      25.5%, 0.261
   Test method                                                                 
    IHC                   8                   2145       0.62 (0.51-0.76)      5.3%, 0.389
    PCR                   1                   94         0.06 (0.01-0.30)      NR

Abbreviations: IHC, immunohistochemistry; NR: not report; MMR, mismatch repair; PCR, polymerase chain reaction.

^a^ Results from random-effect model.

^b^ Bendardaf study was excluded, which was also excluded in subgroup analysis.

Meta-Analysis for DFS {#section11-1533033818808507}
---------------------

In a pooled analysis of 10 DFS studies, deficient MMR was associated with a better prognosis for CRC (HR: 0.62; 95% CI: 0.44-0.88; [Figure 4](#fig4-1533033818808507){ref-type="fig"}). There was significant heterogeneity across 10 studies with DFS (*I* ^2^ = 66.5%, *P* = .001). A meta-regression was performed to explore the source of heterogeneity for DFS. The results showed that all the variables were not related with the heterogeneity ([Table 4](#table4-1533033818808507){ref-type="table"}). The tested content was nearly significant (*P* = .077). In addition, Bendardaf study included 73 patients, and thymidylate synthase (TS) and MMR expressions were assessed for each patient.^[@bibr27-1533033818808507]^ Its HR was calculated by comparing 18 patients with both high TS and MMR expression with 27 patients with both low TS and MMR, while other patients with low MMR and high TS or high MMR and low TS were excluded. This may result in significant heterogeneity between Bendardaf study and other studies (*P* = .001). Thus, Bendardaf study was excluded in subgroup analysis.

![Forest plot for the association between MMR expression and DFS in CRC. CRC indicates colorectal cancer; DFS, disease-free survival; MMR; mismatch repair.](10.1177_1533033818808507-fig4){#fig4-1533033818808507}

###### 

The results of meta-regression for DFS.

![](10.1177_1533033818808507-table4)

                     Coefficient   95% CI              *P*
  ------------------ ------------- ------------------- ------
  Patients           −0.149        (−1.196 to 0.898)   .681
  Country            −0.124        (−1.812 to 1.563)   .830
  Sample size        −0.723        (−2.387 to 0.940)   .260
  Subtypes of gene   −0.220        (−1.140 to 0.699)   .501
  Test content       3.157         (−0.626 to 6.940)   .077
  Analysis method    −0.501        (−2.196 to 1.195)   .417

Abbreviation: CI, confidence interval.

The combined HRs for studies without Bendardaf study were 0.57 (95% CI: 0.50-0.73; *I* ^2^ = 48.0%, *P* = .052). The HRs of deficient MMR on DFS in Asian studies or western studies were 0.62 (95% CI: 0.50-0.78; [Figure 5](#fig5-1533033818808507){ref-type="fig"}) and 0.55 (95% CI: 0.38-0.81; [Figure 5](#fig5-1533033818808507){ref-type="fig"}). The HR was 0.61 (95% CI: 0.47-0.79) for MMR as a marker in 5 studies, 0.32 (95% CI: 0.17-0.58) for hMLH1 as a marker in 2 studies, and 0.72 (95% CI: 0.52-1.00) for hMSH2 as a marker in 3 studies ([Table 3](#table3-1533033818808507){ref-type="table"}; [Figure 5](#fig5-1533033818808507){ref-type="fig"}). When the subgroups were analyzed based on the test method, the combined HRs for IHC and PCR were 0.62 (95% CI: 0.51-0.76) and 0.06 (95% CI: 0.01-0.30), respectively ([Figure 5](#fig5-1533033818808507){ref-type="fig"}).

![Subgroup analysis for the association between MMR expression and DFS in CRC. A, different geographical regions (Asia, west); (B) different subtypes of gene (MMR, hMSH2, hMLH1); (C) different methods for detection of MMR (immunohistochemistry \[IHC\], polymerase chain reaction \[PCR\]). CRC indicates colorectal cancer; DFS, disease-free survival; MMR; mismatch repair.](10.1177_1533033818808507-fig5){#fig5-1533033818808507}

The publication bias was not significant (OS, *P* = .113; DFS, *P* = .210). However, one study was out of the reference line in the DFS group indicated that there might be publication bias for DFS ([Figure 6](#fig6-1533033818808507){ref-type="fig"}).

![Begg funnel plot (A: OS, *P* = .113; B: DFS, *P* = .210). DFS indicates disease-free survival; OS, overall survival.](10.1177_1533033818808507-fig6){#fig6-1533033818808507}

Discussion {#section12-1533033818808507}
==========

Our pooled results from all the eligible studies showed that the HR was 0.59 for OS and 0.62 for DFS, with all showing statistically significant associations between MMR and CRC. The results indicated that deficient MMR was associated with better OS and DFS in the patients with CRC. Meanwhile, subgroup analysis of the different regions (Western and Asia) MMR showed consistent results. In addition, no obvious publication bias was determined by Begg test. These analyses enhanced the reliability of this meta-analysis.

Mismatch repairs are a group of enzymes that can recognize and repair mismatched base pairs during DNA replication, including hMLH1, hMSH2, hMSH3, hMSH6, hPMSH1, and hPMSH2, which are considered critical proteins for the formation of MSI.^[@bibr9-1533033818808507][@bibr10-1533033818808507][@bibr11-1533033818808507][@bibr12-1533033818808507][@bibr13-1533033818808507][@bibr14-1533033818808507][@bibr15-1533033818808507][@bibr16-1533033818808507][@bibr17-1533033818808507]-[@bibr18-1533033818808507],[@bibr21-1533033818808507][@bibr22-1533033818808507][@bibr23-1533033818808507][@bibr24-1533033818808507][@bibr25-1533033818808507][@bibr26-1533033818808507][@bibr27-1533033818808507][@bibr28-1533033818808507][@bibr29-1533033818808507][@bibr30-1533033818808507]-[@bibr31-1533033818808507]^ Mismatch repairs, along with MSI, are proposed to be useful markers in CRC. Approximately 90% hereditary nonpolyposis CRC and 10% to 20% of sporadic CRC demonstrate MSI.^[@bibr32-1533033818808507]^ The vast majority of CRC with MSI is caused by aberrant hMLH1 expression (70% to 95%), while others primarily result from the inactivation of hMSH2 and hMSH6. Additionally, in sporadic CRC, approximately 95% deficient hMLH1 expression is due to hypermethylation of the hMLH1 promoter.^[@bibr33-1533033818808507],[@bibr34-1533033818808507]^

In this meta-analysis, some studies defined negative hMLH1 or hMSH2 expression as MMR deficiency, and they demonstrated a significantly longer OS for patients with deficient MMR.^[@bibr7-1533033818808507],[@bibr14-1533033818808507],[@bibr16-1533033818808507],[@bibr17-1533033818808507],[@bibr23-1533033818808507],[@bibr28-1533033818808507],[@bibr35-1533033818808507]^ Some studies defined deficient hMLH1 (or hMSH2) expression as deficient MMR and demonstrated the same result for OS. ^[@bibr11-1533033818808507][@bibr12-1533033818808507]-[@bibr13-1533033818808507],[@bibr24-1533033818808507],[@bibr26-1533033818808507]^ Four studies showed longer DFS in the patients with CRC with deficient hMLH1 or hMSH2.^[@bibr14-1533033818808507][@bibr15-1533033818808507]-[@bibr16-1533033818808507],[@bibr28-1533033818808507]^ However, Bendardaf *et al* suggested that deficient MMR demonstrated a shorter DFS. This inconsistency could be explained by combining with other genes (TS) and distinctive clinic features indicating that CRC with deficient MMR is apt to display marked peritumoral and intratumoral lymphocytic infiltration.^[@bibr36-1533033818808507][@bibr37-1533033818808507][@bibr38-1533033818808507]-[@bibr39-1533033818808507]^ To summarize, these results suggest that detection of both hMLH1 and hMSH2 could be used to identify most MMR and could be useful methods to evaluate OS for patients with CRC. However, further studies are required to confirm the relationship between MMR and DFS because of significant heterogeneity.

The prognosis of CRC is strongly associated with tumor stage, tumor site, and treatment. MMR-deficient CRC exhibit distinct clinical and pathological features, including proximal location and early tumor stage.^[@bibr38-1533033818808507],[@bibr40-1533033818808507]^ Further, Scarpa *et al* reported that CRC with MMR deficiency exhibited a higher CD80 expression and CD8+ and Th1 T-cell infiltration.^[@bibr41-1533033818808507]^ *In vitro* silencing of hMSH2, hMLH1, and hMSH6 significantly increased the CD80+ cell rate. These results suggest an enhanced immune surveillance mechanism in the presence of MMR deficiency,^[@bibr41-1533033818808507]^ which may explain the improved OS and DFS for patients with CRC with MMR deficiency. These reports might explain our observations that deficient MMR was associated with better prognosis of patients with CRC. However, MMR-deficient CRC shows poor differentiation and mucinous histology, and strong preclinical and clinical evidence suggests a possible resistance to 5-FU in these tumors. Thus, further studies are required to explore the underlying mechanism of MMR deficiency and better CRC prognosis.

There are 2 broadly accepted methods for aberrant MMR detection including MSI testing by PCR and MMR protein expression analysis by IHC. It has been shown that the results of MMR protein expression by IHC are concordant with DNA-based MSI testing, with a favorable sensitivity and a dramatic specificity.^[@bibr42-1533033818808507]^ Immunohistochemistry is commonly used as an alternative test when a molecular laboratory is not available.^[@bibr43-1533033818808507]^ In addition, IHC for MMR is cost-effective and simple, which can determine the specific protein of MMR.^[@bibr43-1533033818808507]^ In this meta-analysis, most studies adopted the methods of IHC for the detection of aberrant MMR. The subgroup of IHC demonstrated that deficient MMR was a protective factor for the prognosis of CRC, which could predict a longer OS and DFS. As a result, the detection of aberrant MMR by IHC could be a promising method to assess the prognosis of CRC.

There were several limitations in our study. First, the detection of MMR is different among the studies; however, most studies adopted IHC to determine the expression of MMR, and the results were consistent. Second, the definition of aberrant MMR is inconsistent; some studies considered aberrant MMR as negative MMR expression, some selected negative hMLH1 expression alone or negative hMSH2 expression alone, and 2 studies selected negative expression of hMLH1, hMSH2, hMSH6, and hPMS2. This may result in significant heterogeneity among these studies. Third, there is significant heterogeneity among the DFS studies. Although we investigated the influence of each individual study on the overall estimate and conducted a meta-regression and subgroup analysis according to geographical regions and different detection methods, the heterogeneity remained significant in some subgroup analysis and could not be clearly classified. Fourth, some studies did not mention certain vital data, especially the follow-up information, such as studies by Langner E, Jansson A, and Smyth EF, which may influence the reliability of the statistical analysis.

Conclusion {#section13-1533033818808507}
==========

In summary, our pooled results indicated that deficient MMR was associated with a better OS and DFS for the CRC patients. However, large well-designed studies with a uniform method of MMR detection are required to confirm these results.
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CI

:   confidence interval

CRC

:   colorectal cancer

DNA

:   deoxyribonucleic acid

DFS

:   disease-free survival

HR

:   hazard ratio

IHC

:   immunohistochemistry

MMR

:   mismatch repair

MSI

:   microsatellite instability

OS

:   overall survival

PCR

:   polymerase chain reaction

TS

:   thymidylate synthase.
